نتایج جستجو برای: cholinesterase inhibitors

تعداد نتایج: 191405  

Journal: :Journal of psychopharmacology 2017
John T O'Brien Clive Holmes Matthew Jones Roy Jones Gill Livingston Ian McKeith Peter Mittler Peter Passmore Craig Ritchie Louise Robinson Elizabeth L Sampson John-Paul Taylor Alan Thomas Alistair Burns

The British Association for Psychopharmacology coordinated a meeting of experts to review and revise its previous 2011 guidelines for clinical practice with anti-dementia drugs. As before, levels of evidence were rated using accepted standards which were then translated into grades of recommendation A-D, with A having the strongest evidence base (from randomised controlled trials) and D the wea...

Journal: :Indian journal of physiology and pharmacology 1971
S K Bhattacharya A K Sanyal

Journal: :The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2001
C Patterson D B Hogan

Journal: :Evidence-based mental health 2003
Debomoy K Lahiri Martin R Farlow

Data extraction Two reviewers extracted data independently about study methods, sources of bias, and outcomes. Sixteen trials included neuropsychiatric outcomes and 18 included functional measures. Neuropsychiatric outcomes were measured with the Neuropsychiatric Inventory (NPI) and the Alzheimer Disease Assessment Scale, noncognitive (ADAS-noncog). Data were combined using weighted mean differ...

2014
Fiammetta Monacelli Patrizio Odetti Marina Sartini Antonello Parodi Claudio Brunelli Gianmarco Rosa

BACKGROUND/AIM Traditional risk factors, like impaired transmitral flow in diastolic filling [vortex formation time (VFT) as echocardiographic parameter], contribute to Alzheimer's disease (AD). Moreover, we observed that acetylcholinesterase inhibitors provide a significant cardioprotection. We assessed the pathogenetic role of VFT as early cardiovascular risk factor in 23 AD patients and 24 c...

Journal: :ChemistrySelect 2023

Alzheimer's disease (AD) is a devastating syndrome that accounts for 60–70 % of all dementia cases, putting an enormous burden on global healthcare and economy. Unfortunately, there no cure AD, the currently approved drugs are limited in their effects. Given various pathological mechanisms behind “one-target, one-drug” paradigm drug design became obsolete, new paradigm, polypharmacology, emerge...

Journal: :The Medical journal of Australia 2001
William Lam

Clinical trials and independent reviews support the use of cholinesterase inhibitors for treating the symptoms of patients with mild to moderate Alzheimer's disease (AD). Before initiating cholinesterase inhibitor therapy, patients should be thoroughly assessed, and the diagnosis confirmed, preferably by a specialist. Compliance with cholinesterase inhibitor therapy should be monitored and the ...

2007
Tomasz Sobow

Introduction: Considering lack of accepted guideline in cases of Parkinson’s disease-related visual hallucinations with poor response or intolerance to antipsychotics, and their possible cholinergic pathogenesis, the trial with cholinesterase inhibitors seems to be legitimated. Material and methods: Five patients with PD (with or without dementia) complicated by VH and unresponsive to atypical ...

Journal: :Chemical & pharmaceutical bulletin 2010
Liang Yu Rihui Cao Wei Yi Qin Yan Zhiyong Chen Lin Ma Huacan Song

A series of difunctionalized 4-hydroxybenzaldehyde derivatives were designed, synthesized and evaluated as cholinesterase (acetylcholinesterase (AChE) and butyrylcholinesterase (BChE)) inhibitors. The results demonstrated that all the compounds had more potent AChE and BChE inhibitory activities than galanthamine-HBr, one of the best cholinesterase inhibitors known so far. The inhibition mechan...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید